

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

211463US0PCT

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/913721

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/JP00/00856

16 February 2000

17 February 1999

TITLE OF INVENTION

SKIN PREPARATIONS FOR EXTERNAL USE

APPLICANT(S) FOR DO/EO/US

HIRAKI Yoshio et al.


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Notice for Consideration of Documents Cited in International Search Report/Notice of Priority/PCT/IB/304
PCT/IB/308/Declaration of Toshiro SONE/Request for Correction of Inventor's Name

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53(b))		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
09/913721		PCT/JP00/00856		211463US0PCT	
24. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO				\$1000.00	
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO				\$860.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$710.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)				\$690.00	
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than _____ months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	- 20 =	0	x \$18.00	\$0.00	
Independent claims	- 3 =	0	x \$80.00	\$0.00	
Multiple Dependent Claims (check if applicable).			<input checked="" type="checkbox"/>	\$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,130.00	
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$1,130.00	
Processing fee of \$130.00 for furnishing the English translation later than _____ months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
TOTAL NATIONAL FEE =				\$1,130.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				<input type="checkbox"/>	\$0.00
TOTAL FEES ENCLOSED =				\$1,130.00	
				Amount to be refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$1,130.00 to cover the above fees is enclosed.					
b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0030 A duplicate copy of this sheet is enclosed.					
d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
WILLIAM E. BEAUMONT REGISTRATION NUMBER 30,996					
			SIGNATURE		
22850			Norman F. Oblon		
			NAME		
			24,618		
			REGISTRATION NUMBER		
			August 17, 2001		
			DATE		

09/913721

JCO3 Rec'd PCT/TO 17 AUG 2001

21-1463US-0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

:

YOSHIO HIRAKI ET AL

: ATTN: APPLICATION DIVISION

SERIAL NO: NEW U.S. PCTAPPLN

:

(BASED ON PCT/JP00/00856)

FILED: HEREWITH

:

FOR: SKIN PREPARATIONS FOR
EXTERNAL USE

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE SPECIFICATION

Please replace Table 6 on page 19 with the following Table.

Table 6

		Composition			
		1	2	3	4
1	Glyceryl monostearate	--	--	2.0	5.0
2	Glyceryl monopalmitate	0.5	2.0	--	5.0
3	Monostearyl glyceryl ether	0.1	--	0.3	--
4	Monopalmityl glyceryl ether	--	0.5	--	3.0
5	Cholesterol	0.05	0.1	0.2	3.0
6	Retinol palmitate	0.1	--	--	2.0
7	Retinol	--	0.2	--	--
8	Retinoic acid	--	--	0.5	--
9	Calcium chloride	0.1	0.01	0.1	0.2
10	Methylparaben	0.1	0.1	0.1	0.2
11	Glycerol	1.0	1.0	--	--
12	1,3-Butylene glycol	--	--	2.0	2.0
13	Purified water	Balance	Balance	Balance	Balance
14	Polyvinyl pyrrolidone	1.0	0.5	--	--
15	Xanthan gum	--	--	0.1	--
16	Hyaluronic acid	--	--	--	0.1

REMARKS

Claims 1-5 are active in the present application. The specification has been amended to correct a typographical error. No new matter is added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518



22850

(703) 413-3000
Fax #: (703)413-2220
NFO/DJPER/SUKOS/js

I:\atty\SUKOS\211463US0-PR.wpd

21-1463US-0 PCT

Marked-Up Copy

Serial No: _____

Amendment Filed on: 08/17/01IN THE SPECIFICATION

Please replace Table 6 on page 19 with the following Table.

Table 6

		Composition			
		1	2	3	4
1	Glyceryl monostearate	--	--	2.0	5.0
2	Glyceryl monopalmitate	0.5	2.0	--	5.0
3	Monostearyl glyceryl ether	0.1	--	0.3	--
4	Monopalmityl glyceryl ether	--	0.5	--	3.0
5	Cholesterol	0.05	0.1	0.2	3.0
6	Retinol palmitate	0.1	--	--	[0.1] 2.0
7	Retinol	--	0.2	--	--
8	Retinoic acid	--	--	0.5	--
9	Calcium chloride	0.1	0.01	0.1	0.2
10	Methylparaben	0.1	0.1	0.1	0.2
11	Glycerol	1.0	1.0	--	--
12	1,3-Butylene glycol	--	--	2.0	2.0
13	Purified water	Balance	Balance	Balance	Balance
14	Polyvinyl pyrrolidone	1.0	0.5	--	--
15	Xanthan gum	--	--	0.1	--
16	Hyaluronic acid	--	--	--	0.1

DESCRIPTION

SKIN PREPARATIONS FOR EXTERNAL USE

5 TECHNICAL FIELD

The present invention relates to a skin preparation for external use (hereinafter may also be referred to as "external skin care composition") which has a high moisturizing effect, high effects of relieving or improving skin roughness and suppressing wrinkling, etc., shows neither any offensive smell nor stickiness, gives users a dry feel upon use, and exhibits controlled foaming upon production thereof and excellent stability.

15 BACKGROUND ART

The skin is delicately affected by aging, and external environments such as temperature, humidity and ultraviolet rays, etc. Therefore, the decrement of various functions of the skin, and aging of the skin are brought about, and various troubles such as wrinkling and skin roughness occur. In order to improve these cutaneous troubles, it has been attempted to incorporate various components having a skin roughness-improving effect and an anti-aging effect, such as synthetic or natural moisturizing components, natural extracts such as sesame oil, rutin sugar derivatives, proteins such as sericin, and α -hydroxy acids into external skin care compositions

such as cosmetic compositions.

For example, polyhydric alcohols such as glycerol and propylene glycol; saccharides such as sorbitol and maltitol; amino acids; polymeric substances such as
5 hyaluronic acid and chondroitin sulfate; etc. are known as the moisturizing components. However, the use of these moisturizing agents involves a problem that a sticky feel is given users.

The present applicant found and discloses that a
10 lamellar structure comprising a fatty acid monoglyceride as a main component has a high moisturizing effect (Japanese Patent Registration No. 2606761). However, occurrence of foaming is unavoidable in the production of this lamellar structure, which becomes a problem from the
15 viewpoint of production efficiency. In addition, there may be offered a problem that a part of the lamellar structure is destroyed according to conditions of storage.

Japanese Patent Application Laid-Open No.
500355/1989 through PCT route discloses a method for
20 preventing or improving changes or damages of the skin due to skin aging and/or exposure to sunlight by incorporating vitamin A or a derivative thereof. However, vitamin A is insufficient in effects of improving skin roughness and suppressing wrinkling and also involves a problem that it
25 forms the cause of offensive smell and stickiness.

It is therefore an object of the present invention to provide a skin preparation for external use which has

high effects of improving skin roughness and suppressing wrinkling, etc., shows neither any offensive smell nor stickiness, and exhibits controlled foaming upon production thereof.

5

DISCLOSURE OF THE INVENTION

The present inventors have carried out an extensive investigation with a view toward solving the above-described problems. As a result, it has been found that
10 when a lamellar structure comprising a fatty acid monoglyceride as a main component and vitamin A or a derivative thereof are used in combination, the effects of vitamin A on improvement in skin roughness, suppression of wrinkling, etc. are enhanced, and the resulting
15 composition gives users a dry feel upon use and that when an oil phase mixture containing a fatty acid monoglyceride and vitamin A is prepared and a lamellar structure is then prepared from the oil phase mixture, higher effects of improving skin roughness and suppressing wrinkling are
20 achieved, and the smell of vitamin A, foaming upon the production of the lamellar structure can be suppressed, and moreover shelf stability of the resulting external skin care composition is also improved, thus leading to completion of the present invention.

25 Thus, the present invention provides an external skin care composition comprising a lamellar structure containing a fatty acid monoglyceride as a main component,

and vitamin A or a derivative thereof.

BEST MODE FOR CARRYING OUT THE INVENTION

Examples of the fatty acid monoglyceride used in the present invention include monoglycerides of saturated or unsaturated fatty acids having 8 to 18 carbon atoms. Among these, myristic acid monoglyceride, palmitic acid monoglyceride and stearic acid monoglyceride are preferred. These monoglycerides may be used either singly or in any combination thereof.

The lamellar structure used in the present invention contains the fatty acid monoglyceride as a main component. As constitutive components of the lamellar structure, other components may be used in addition to the fatty acid monoglyceride. Such constitutive components include cholesterol and the like. The incorporation of cholesterol is particularly preferred for the purpose of improving the stability of the lamellar structure. The amount of cholesterol added is preferably 0.01 to 1 part by weight, particularly 0.05 to 0.40 parts by weight per part by weight of the fatty acid monoglyceride.

In the present invention, the lamellar structure is prepared by using the fatty acid monoglyceride or an oil phase mixture containing the fatty acid monoglyceride as a raw material. For example, the fatty acid monoglyceride or the oil phase mixture containing the fatty acid monoglyceride is heated to melt and mix it into a state of

a liquid crystal, and a water phase kept at substantially the same temperature is then added to the oil phase to disperse the oil phase in the water phase by physically stirring the mixture, whereby a dispersion of the lamellar structure used in the present invention can be prepared.

The heating temperature is preferably 45 to 100°C, more preferably 45 to 80°C, particularly 50 to 70°C. The physical stirring in this process is preferably conducted by using an atomizing device such as an ultrasonic emulsifier, high-pressure, homogeneously dispersing device, nanomizer, homomixer, homogenizer, colloid mill or high-speed stirrer. As an alternative process, the lamellar structure used in the present invention may also be prepared by dissolving the fatty acid monoglyceride or the oil phase mixture containing the fatty acid monoglyceride in a solvent such as dichloromethane, chloroform or acetone, distilling off the solvent in a rotating container to deposit a lipid layer, and then adding and mixing water or a proper aqueous solution to and with the lipid. Between both preparation processes, the former process is preferred from the viewpoint of industrial production.

No particular limitation is imposed on the form of the lamellar structure. However, the same form as a vesicle, i.e., a closed lamellar structure is preferred. Such a closed lamellar structure is preferably a multi-lamellar structure, not a unilamellar structure.

No particular limitation is imposed on the vitamin A or the derivative thereof (hereinafter referred to as "vitamin A" merely) used in the present invention, and any of retinol, retinal of the aldehyde type, retinoic acid of the carboxylic acid type, and esters such as retinol acetate and retinol palmitate may be preferably used. Besides, vitamin A precursors such as β -carotin and decomposed products of vitamin A, such as hydroretinol, retroretinol and isoanhydroretinol may also be used. Among these, retinol palmitate, retinol, retinoic acid and retinol acetate preferred from the viewpoint of effects of improving skin roughness and suppressing wrinkling, with retinol palmitate being particularly preferred. These compounds may be used either singly or in any combination thereof.

With respect of contents of the fatty acid monoglyceride and vitamin A in the external skin care composition according to the present invention, the content of the fatty acid monoglyceride is preferably 0.1 to 25% by weight, particularly 0.5 to 10% by weight from the viewpoint of stability of the lamellar structure, while the content of the vitamin A is preferably 0.001 to 2% by weight, particularly 0.01 to 0.3% by weight from the viewpoints of the effects of improving skin roughness and suppressing wrinkling, cost and workability.

The external skin care composition according to the present invention may also be prepared by preparing the

lamellar structure and then incorporating it together with the vitamin A and other components into the external skin care composition. However, it is preferable to first prepare an oil phase mixture containing the fatty acid

5 monoglyceride and vitamin A, prepare the lamellar structure from this oil phase mixture according to the process described above and then incorporate it together with other components into the external skin care composition. The effects of the vitamin A on improvement
10 in skin roughness and suppression of wrinkling are enhanced by any process. However, these effects are particularly enhanced by preparing the lamellar structure from the mixture of the fatty acid monoglyceride and vitamin A. According to this process, the offensive smell
15 caused by the vitamin A can be suppressed, foaming occurred upon the production of the lamellar structure can also be suppressed, and moreover the stability of the lamellar structure is enhanced, thereby providing an external skin care composition excellent in shelf
20 stability.

Viewing from the state of the vitamin A in the external skin care composition, the vitamin A is preferably contained within or covered with the lamellar structure from the above-described point of view.

25 When the lamellar structure is prepared from the oil phase mixture containing the fatty acid monoglyceride and vitamin A as described above, the mixing ratio of the

fatty acid monoglyceride to the vitamin A is preferably 2 to 100 parts by weight, particularly 5 to 50 parts by weight for the fatty acid monoglyceride per part by weight of the vitamin A from the viewpoints of the degree of suppression of foaming, stability to storage, etc. More specifically, if the content of the fatty acid monoglyceride is higher than this range, the effect of suppressing foaming upon the production is lessened. If the content is lower than this range on the other hand, the stability of the lamellar structure is deteriorated.

The external skin care compositions according to the present invention obtained in such a manner can be used as cosmetics, drugs, quasi-drugs, medicines for external use, etc. Among these, they are preferably used as cosmetics for improving skin roughness, suppressing wrinkling or preventing aging. No particular limitation is imposed on the form of such cosmetics, and they may be used in various forms, for example, toilet waters, emulsified compositions, moisturizing creams, cleansing creams, massaging creams, face cleansing creams, packs, beauty lotions, hair cosmetics, mouth cosmetics, etc.

Into the external skin care compositions according to the present invention, may be incorporated publicly known cosmetic components and drug components, for example, water, alcohols, surfactants, preservatives, perfume bases, coloring matter, various kinds of medicinally-effective components, etc. so far as no detrimental influence is

thereby imposed on the effects of the present invention.

EXAMPLES

The present invention will hereinafter be described in more detail by the following examples. However, the present invention is not limited to these examples.

Test Example 1: Wrinkling-suppressing test

An influence of the following samples on the skin roughness and wrinkling of hairless mice by exposure to an ultraviolet ray.

10 (Preparation of sample)

Invention Product 1:

(1) A phase: After a fatty acid monoglyceride (d) and cholesterol (e) of 1A as shown in Table 1 were heated at 80°C and mixed into a solution, and the resultant solution was cooled to 65°C, the solution was added to a solution with calcium chloride (a) and methylparaben (b) dissolved in purified water (c) at 60°C, and the resultant mixture was stirred and mixed by a homomixer to obtain a dispersion of a lamellar structure.

20 (2) B phase: Calcium chloride (a), methylparaben (b) and purified water (c) of 1B as shown in Table 1 were heated at 80°C and mixed into a solution. On the other hand, retinol palmitate (f), liquid paraffin (g) and surfactants (h, i) were also heated at 80°C and mixed into a solution. Both solutions were stirred and mixed with each other and then cooled to obtain an emulsion.

(3) The A phase and B phase were stirred and mixed

at room temperature to obtain an emulsified composition
(Invention Product 1).

Invention Product 2:

(1) A phase: After a fatty acid monoglyceride (d),
5 cholesterol (e) and retinol palmitate (f) of 2A as shown
in Table 1 were heated at 80°C and mixed into a solution,
and the resultant solution was cooled to 65°C, the solution
was added to a solution with calcium chloride (a) and
methylparaben (b) dissolved in purified water (c) at 60°C,
10 and the resultant mixture was stirred and mixed by a
homomixer to obtain a dispersion of a lamellar structure.

(2) B phase: Calcium chloride (a), methylparaben (b)
and purified water (c) of 1B as shown in Table 1 were
heated at 80°C and mixed into a solution. On the other
15 hand, liquid paraffin (g) and surfactants (h, i) were also
heated at 80°C and mixed into a solution. Both solutions
were stirred and mixed with each other and then cooled to
obtain an emulsion.

(3) The A phase and B phase were stirred and mixed
20 at room temperature to obtain an emulsified composition
(Invention Product 2).

Comparative Product 1:

Calcium chloride (a), methylparaben (b) and purified
water (c) of 3A as shown in Table 1 were heated at 80°C and
25 mixed into a solution. On the other hand, retinol
palmitate (f), liquid paraffin (g) and surfactants (h, i)
were also heated at 80°C and mixed into a solution. Both

solutions were stirred and mixed with each other and then cooled to obtain an emulsified composition (Comparative Product 1).

Table 1

	Invention product 1		Invention product 2		Comparative product 1
	1A (lame- lla)	1B (emul- sion)	2A (lame- lla)	2B (emul- sion)	3B (emulsion)
a. Calcium chloride	0.05	0.05	0.05	0.05	0.1
b. Methylparaben	0.05	0.05	0.05	0.05	0.1
c. Purified water	43.5	34.9	42.4	35.9	84.8
d. Poem s-100 ¹⁾	5.0	-	5.0	-	-
e. Cholesterol	1.5	-	1.5	-	-
f. Retinol palmitate	-	1.0	1.0	-	1.0
g. Liquid paraffin	-	10.0	-	10.0	10.0
h. TS-10 ²⁾	-	2.0	-	2.0	2.0
i. SS-10 ³⁾	-	2.0	-	2.0	2.0

- 5 1) A mixture of glyceryl monostearate and glyceryl
monopalmitate (product of Riken Vitamin Co., Ltd.)
- 2) Polyoxyethylene sorbitan monostearate (product of Nikko
Chemicals Co., Ltd.)
- 3) Sorbitan monostearate (product of Nikko Chemicals Co.,
10 Ltd.)
- (Testing method)

Forty hr-1 female hairless mice (aged 6 weeks)
reared by freely giving ordinary solid feed and water in a
thermo-hygrostatic breeding chamber controlled to 24±2°C
15 and 55±10% RH were divided into 4 groups each consisting
of 10 mice and used.

These mice were exposed to an ultraviolet ray (UVB) 3 times a week under conditions of 40 to 160 mJ/cm². The samples shown in Table 1 was applied to mice of the respective groups every day in a dose of 10 μ l/cm² to
5 determine the degree of wrinkles after 14 days, 28 days and 42 days. Incidentally, the dose of the ultraviolet ray was increased stepwise within the above range.

The determination of wrinkles was conducted in the following manner. Namely, the shapes of the wrinkles were
10 taken as replicas, and measurement of the wrinkles were computer-processed by means of an image analyzer to find a proportion (wrinkle percent) of an area of the wrinkles to the whole area. A relative value of each sample-applied group was calculated out from an average value of
15 differences (increments of wrinkle percent) between the respective wrinkle percent after 14 days, 28 days and 42 days and the wrinkle percent before the exposure to the ultraviolet ray regarding a value as to a control group, to which no sample had been applied, as 100, thereby
20 determining the average rate of wrinkling in each group.
(Result)

As a result, the external skin care compositions according to the present invention exhibited a higher effect of suppressing wrinkling than Comparative Product 1
25 (retinol palmitate alone) containing no lamellar structure, and the effect was particularly marked in Invention Product 2 in which the lamellar structure had been

prepared together with retinol palmitate.

Table 2

	Average value of increments of wrinkle percent after 14, 28 and 42 days	Average rate of wrinkling
Control (no application)	1.827	100
Comparative Product 1	1.472	80.6
Invention Product 1	1.386	75.9
Invention Product 2	0.922	50.5

Test Example 2: Foaming test and shelf stability test

5 Dispersions of a lamellar structure were prepared in the same formulation and process as in Invention Product 2 of Test Example 1 except that the amounts of the vitamin A and fatty acid monoglyceride added were changed in various combinations, to confirm the foaming tendency upon the production thereof and stability to storage.

(Evaluation method and standard)

Foaming tendency:

Foaming occurred upon the production was visually observed to judge the foaming tendency in accordance with

15 the following standard:

- 0: Not foamed;
- 1: Somewhat foamed;
- 2: Foamed;
- 3: Considerably foamed.

20 Stability:

A state of deterioration of a vesicle after each dispersion of the lamellar structure was stored for 2 weeks or 4 weeks at 40°C was observed through a microscope to judge the stability in accordance with the following

5 standard:

- 0: Not deteriorated;
- 1: Srayly deteriorated;
- 2: Deteriorated;
- 3: Considerably deteriorated.

10 (Result)

As a result, the foaming tendency was suppressed in the case where the fatty acid monoglyceride was incorporated in a proportion of at most 100 times by weight, particularly at most 50 times by weight as much as the vitamin A (Table 3). The stability to storage was good in the case where the fatty acid monoglyceride was incorporated in a proportion of at least twice by weight, particularly at least 5 times by weight as much as the vitamin A (Table 4).

20

Table 3: Foaming tendency

[illegible]

Table 4: Stability

		Concentration of fatty acid monoglyceride (% by weight)								
		0.1	0.2	0.5	1.0	5.0	10.0	20.0	25.0	30.0
Concentration of vitamin A (% by weight)	0	0	0	0	0	0	0	0	0	1
	0.005	0	0	0	0	0	0	0	1	1
	0.01	1	0	0	0	0	0	0	1	1
	0.05	2	1	0	0	0	0	0	1	1
	0.1	3	2	1	0	0	0	0	1	1
	0.2	3	3	2	0	0	0	0	1	1
	0.5	3	3	3	1	0	0	0	1	1
	1.0	3	3	3	3	0	0	1	1	1
	2.0	3	3	3	3	1	1	1	1	1
	5.0	3	3	3	3	3	3	2	2	2
	10.0	3	3	3	3	3	3	3	3	3
	20.0	3	3	3	3	3	3	3	3	3

Test Example 3: Smell suppressing test

With respect to compositions prepared in accordance
 5 with the following preparation process, the degree of
 smell of the vitamin A, which is not very preferable as
 cosmetic, was got to be evaluated by 10 expert panelists
 in accordance with the following standard:

(Preparation process)

10 a or b, and c and d in the formulation shown in
 Table 5 were mixed and headed to 80°C into a solution. e
 and f were then mixed with g and heated to 60°C into a

solution. This solution was placed in a paddle agitator mixer equipped with a homomixer rotating at a high speed, and the above-prepared mixture of a or b, and c and d was added to the solution with stirring. After the resultant mixture was fully stirred at a high speed, the mixture was gradually cooled to room temperature.

(Evaluation standard)

0: Not smelled;

1: Srayly smelled;

2: Smelled;

3: Considerably smelled.

(Result)

The results are shown as average values in Table 5.

Table 5

			Invention Product 3	Comparative Product 2
Formulation (% by weight)	a	Soybean lecithin	-	6.0
	b	Glyceryl monopalmitate	6.0	-
	c	Cholesterol	0.6	0.6
	d	Retinol palmitate	0.3	0.3
	e	Sodium chloride	0.1	0.1
	f	Methylparaben	0.1	0.1
	g	Purified water	92.9	92.9
Smell right after preparation			0.44	1.24
Smell after 2 weeks at 40°C			0.92	2.18
Smell after 4 weeks at 40°C			1.30	2.68

As apparent from Table 5, the lamellar structure prepared by the fatty acid monoglyceride in the invention product was markedly prevented from emitting smell from the vitamin A upon the preparation and after several days
5 elapsed compared with the liposome preparation of the comparative product prepared by lecithin which is a soybean phospholipid.

Preparation Example:

Their corresponding raw materials 1 to 8 shown in
10 Table 6 were heated at 60 to 85°C and mixed with one another. On the other hand, raw materials 9 to 12 and a part of purified water (13) were heated to 60°C and mixed. To the mixture, was added the above-prepared mixed solution of the raw materials 1 to 8. The resulting
15 mixtures were subjected to a mixing treatment by means of a homomixer for Composition 1, a high-pressure homogenizer for Composition 2, a high-speed stirrer for Composition 3 and an ultrasonic dispersing machine for Composition 4. Each of the mixtures was then mixed with raw materials 14
20 to 16 and the remainder of the purified water (13) under cooling, and the temperature thereof was returned to room temperature, thereby obtaining the respective compositions.

Table 6

		Composition			
		1	2	3	4
1	Glyceryl monostearate	-	-	2.0	5.0
2	Glyceryl monopalmitate	0.5	2.0	-	5.0
3	Monostearyl glyceryl ether	0.1	-	0.3	-
4	Monopalmityl glyceryl ether	-	0.5	-	3.0
5	Cholesterol	0.05	0.1	0.2	3.0
6	Retinol palmitate	0.1	-	-	0.1
7	Retinol	-	0.2	-	-
8	Retinoic acid	-	-	0.5	-
9	Calcium chloride	0.1	0.01	0.1	0.2
10	Methylparaben	0.1	0.1	0.1	0.2
11	Glycerol	1.0	1.0	-	-
12	1,3-Butylene glycol	-	-	2.0	2.0
13	Purified water	Balance	Balance	Balance	Balance
14	Polyvinyl pyrrolidone	1.0	0.5	-	-
15	Xanthan gum	-	-	0.1	-
16	Hyaluronic acid	-	-	-	0.1

Example 1: Cosmetic lotion

The following components were mixed in accordance
 5 with a method known *per se* in the art to prepare a
 cosmetic lotion.

	Composition 1	80 (wt.%)
	Ethanol	5
	Glycerol	5
10	1,3-Butylene glycol	5
	Methylparaben	0.05
	Polyoxyethylene sorbitan monooleate	0.5
	Carboxyvinyl polymer	0.1
	Sodium hyaluronate	0.01
15	Perfume base	0.05
	Purified water	Balance.

Example 2: Cosmetic milk

The following components were mixed in accordance with a method known *per se* in the art to prepare an cosmetic milk.

	Composition 2	50 (wt.%)
5	Stearic acid	2
	Cetanol	1
	Vaseline	5
	Liquid paraffin	10
	Polyoxyethylene sorbitan monooleate	2
10	Sorbitan monostearate	2
	Butylparaben	0.1
	1,3-Butylene glycol	5
	Carboxymethyl cellulose	0.1
	Sodium hydroxide	0.05
15	Methylparaben	0.1
	Perfume base	0.05
	Purified water	Balance.

Example 3: Cosmetic cream

The following components were mixed in accordance with a method known *per se* in the art to prepare a cosmetic cream.

	Composition 4	50 (wt.%)
	Stearic acid	4
	Cetanol	2
25	Vaseline	5
	Liquid paraffin	10
	Jojoba oil	5

	polyoxyethylene behenyl ether	3
	Sorbitan monostearate	3
	Butylparaben	0.1
	1,3-Butylene glycol	2
5	Sodium hydroxide	0.05
	Methylparaben	0.1
	Perfume base	0.05
	Purified water	Balance.

Example 4: Beauty essence

10 The following components were mixed in accordance with a method known *per se* in the art to prepare a beauty essence.

	Composition 3	20 (wt.%)
	Xanthan gum	0.4
15	Sodium hyaluronate	0.05
	Ethanol	5
	Glycerol	2
	Paraben	0.05
	Sorbitan polyoxyethylene monooleate	0.5
20	Perfume base	0.05
	Purified water	Balance.

Example 5: Face washing cream

25 The following components were mixed in accordance with a method known *per se* in the art to prepare a face washing cream.

	Composition 2	5 (wt.%)
	Stearic acid	10

	Palmitic acid	10
	Myristic acid	12
	Lauric acid	4
	Oleyl alcohol	1.5
5	Butylparaben	0.1
	Methylparaben	0.1
	Perfume base	0.5
	Glycerol	18
	Potassium hydroxide	6
10	Purified water	Balance.

Example 6: Pack

The following components were mixed in accordance with a method known *per se* in the art to prepare a pack.

	Composition 4	1 (wt.%)
15	Polyvinyl alcohol	15
	Sodium carboxymethyl cellulose	5
	Propylene glycol	3
	Ethanol	10
	Methylparaben	0.1
20	Purified water	Balance.

Example 7: Cleansing cream

The following components were mixed in accordance with a method known *per se* in the art to prepare a cleansing cream.

25	Composition 3	5 (wt.%)
	Paraffin	10
	Beeswax	3

	Vaseline	15
	Liquid paraffin	41
	Sorbitan sesquioleate	4.2
	Polyoxyethylene sorbitan monooleate	0.8
5	(20 E.O.)	
	Butylparaben	0.1
	Methylparaben	0.1
	Perfume base	0.5
	Purified water	Balance.

10 Example 8: Massaging cream

Among the following components, raw materials 1 to 4 were heated at 85°C and mixed, and raw materials 5 and 6, and a part of purified water 18 were heated to 60°C and mixed. Both mixtures were mixed and the resultant mixture was treated by a homogenizer.

On the other hand, raw materials 7 to 14 were heated at 80°C and mixed, and raw materials 15 and 16, and the remainder of purified water 18 were heated to 80°C and mixed. Both mixtures were mixed, stirred and then cooled. A raw material 17 was added when this mixed solution (raw materials 7 to 16 and 18) was cooled to 50°C, and the resultant mixture was mixed with the above-prepared mixed solution (raw materials 1 to 6 and 18) at 40°C to prepare a massaging cream.

25	1 Glyceryl monostearate	0.5 (wt.%)
	2 Glyceryl monopalmitate	0.5
	3 Monopalmityl glyceryl ether	0.3

	4	Cholesterol	0.3
	5	Calcium chloride	0.02
	6	1,3-Butylene glycol	0.02
	7	Paraffin	4
5	8	Microcrystalline wax	6
	9	Beeswax	6
	10	Vaseline	14
	11	Liquid paraffin	42.5
	12	Sorbitan sesquioleate	3.7
10	13	Polyoxyethylene sorbitan monooleate (20 E.O.)	0.8
	14	Butylparaben	0.1
	15	Methylparaben	0.1
	16	Soap powder	0.3
15	17	Perfume base	0.5
	18	Purified water	Balance.

INDUSTRIAL APPLICABILITY

The external skin care compositions according to the
 present invention have excellent effects of improving skin
 roughness and suppressing wrinkling, since a lamellar
 structure composed mainly of a fatty acid monoglyceride
 and a vitamin A are used in combination. Further, the
 effects of improving skin roughness and suppressing
 wrinkling are more enhanced, and moreover foaming occurred
 upon the production of the lamellar structure and smell of
 the vitamin A, which is not preferable as cosmetic, can be

suppressed by preparing the lamellar structure from an oil phase mixture containing the fatty acid monoglyceride and vitamin A. In addition, the stability of the resulting external skin care composition can be improved.

CLAIMS

1. A skin preparation for external use, comprising a
lamellar structure containing a fatty acid monoglyceride
5 as a main component, and vitamin A or a derivative thereof.

2. The skin preparation for external use according
to Claim 1, which comprises a lamellar structure prepared
from an oil phase mixture containing the fatty acid
monoglyceride and vitamin A or the derivative thereof.

10 3. The skin preparation for external use according
to Claim 1, wherein vitamin A or the derivative thereof is
contained within or covered with the lamellar structure
composed mainly of the fatty acid monoglyceride.

15 4. The skin preparation for external use according
to Claim 1, wherein the mixing ratio of the fatty acid
monoglyceride to vitamin A or the derivative thereof is 2
to 100 parts by weight for the fatty acid monoglyceride
per part by weight of vitamin A or the derivative thereof.

20 5. The skin preparation for external use according
to any one of Claims 1 to 4, which is a cosmetic.

ABSTRACT

The invention relates to a skin preparation for external use, which contains a lamellar structure containing a fatty acid monoglyceride as a main component, and vitamin A or a derivative thereof. The skin preparation for external use has high effects of improving skin roughness and suppressing wrinkling, etc., shows neither any offensive smell nor stickiness, and exhibits controlled foaming upon the production thereof.

Declaration and Power of Attorney For Patent Application

1516
(10000000)

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者（下記の名称が複数の場合）であると信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled.

SKIN PREPARATIONS FOR EXTERNAL USE

上記発明の明細書は、

☐ 本書に添付されています。

the specification of which

☐ is attached hereto.

☒ ____月____日に提出され、米国出願番号または特許協定条約国際出願番号を____とし、
(該当する場合) ____に訂正されました。

☒ was filed on 16 February 2000
as United States Application Number or
PCT International Application Number
PCT/JP00/00856 and was amended on
____ (if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Japanese Language Declaration

(日本語宣言書)

私は、米国法典第35編119条 (a) - (d) 項又は365条 (b) 項に基づき下記の、米国以外の国の少なくとも一カ国を指定している特許協力条約365 (a) 項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)

外国での先行出願

<u>11-38392</u>	<u>JAPAN</u>
(Number) (番号)	(Country) (国名)
<u> </u>	<u> </u>
(Number) (番号)	(Country) (国名)

私は、第35編米国法典119条 (e) 項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

<u> </u>	<u> </u>
(Application No.) (出願番号)	(Filing Date) (出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約365条 (c) に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

<u>PCT/JP00/00856</u>	<u>16 February 2000</u>
(Application No.) (出願番号)	(Filing Date) (出願日)

<u> </u>	<u> </u>
(Application No.) (出願番号)	(Filing Date) (出願日)

私は、私自信の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じることに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Claimed

優先権主張

<u>17 February 1999</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Day/Month/Year Filed) (出願年月日)	Yes はい	No いいえ
<u> </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Day/Month/Year Filed) (出願年月日)	Yes はい	No いいえ

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

<u> </u>	<u> </u>
(Application No.) (出願番号)	(Filing Date) (出願日)

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

<u> </u>
(Status: Patented, Pending, Abandoned) (現況: 特許許可済、係属中、放棄済)

<u> </u>
(Status: Patented, Pending, Abandoned) (現況: 特許許可済、係属中、放棄済)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Japanese Language Declaration
(日本語宣言書)

委任状：私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。
(弁理士、または代理人の指名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: (list name and registration number)



022850

書類送付先

Send Correspondence to:



022850

直接電話連絡先：(名前及び電話番号)

Direct Telephone Calls to: (name and telephone number)

(703) 413-3000

単独発明者または第一の共同発明者の氏名	1-00	Full name of sole or first joint inventor	Yoshio HIRAKI
発明者の署名	日付	Inventor's signature	Yoshio Hiraki
住所		Date	June 14, 2001
国籍		Residence	c/o Kabushiki Kaisha Yakult Honsha 1-19, Higashishinbashi 1-chome, Minato-ku, Tokyo 105-8660 JAPAN
郵便の宛先		Citizenship	JAPAN
		Post Office Address	SAME AS ABOVE
第二の共同発明者の氏名	2-00	Full name of second joint inventor, if any	Satoshi YOSHIKAWA
第二の共同発明者の署名	日付	Second joint Inventor's signature	Satoshi Yoshikawa
住所		Date	June 14, 2001
国籍		Residence	c/o Kabushiki Kaisha Yakult Honsha 1-19, Higashishinbashi 1-chome, Minato-ku, Tokyo 105-8660 JAPAN
郵便の宛先		Citizenship	JAPAN
		Post Office Address	SAME AS ABOVE

(第三以降の共同発明者についても同様に記載し、署名すること)

(Supply similar information and signature for third and subsequent joint inventors.)

Japanese Language Declaration
(日本語宣言書)

第三の共同発明者の氏名	3-00	Full name of third joint inventor, if any Takashi KINOSHITA
第三の共同発明者の署名	日付	Third joint inventor's signature <i>Takashi Kinoshita</i> Date June 14, 2001
住所		Residence c/o Kabushiki Kaisha Yakult Honsha 1-19, Higashishinbashi 1-chome, Minato-ku,
国籍		Tokyo 105-8660 JAPAN Citizenship JAPAN JPX
郵便の宛先		Post Office Address SAME AS ABOVE

第四の共同発明者の氏名	14-00	Full name of fourth joint inventor, if any Tatsutoshi SHIRAISHI
第四の共同発明者の署名	日付	Fourth joint inventor's signature <i>Tatsutoshi Shiraishi</i> Date June 14, 2001
住所		Residence c/o Kabushiki Kaisha Yakult Honsha 1-19, Higashishinbashi 1-chome, Minato-ku,
国籍		Tokyo 105-8660 JAPAN Citizenship JAPAN JPX
郵便の宛先		Post Office Address SAME AS ABOVE

第五の共同発明者の氏名	3-00	Full name of fifth joint inventor, if any Toshiro SONE
第五の共同発明者の署名	日付	Fifth joint inventor's signature <i>Toshiro Sone</i> Date June 14, 2001
住所		Residence c/o Kabushiki Kaisha Yakult Honsha 1-19, Higashishinbashi 1-chome, Minato-ku,
国籍		Tokyo 105-8660 JAPAN Citizenship JAPAN JPX
郵便の宛先		Post Office Address

第六の共同発明者の氏名		Full name of sixth joint inventor, if any
第六の共同発明者の署名	日付	Sixth joint inventor's signature Date
住所		Residence
国籍		Citizenship
郵便の宛先		Post Office Address

(第六またはそれ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)